NEW YORK, April 17, 2018 /PRNewswire/ — WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on OCUL, ONTX, OPK, and OTIC which can be accessed for free by signing up to www.wallstequities.com/registration. Featured today on WallStEquities.com is the Biotech sector, which harnesses biological processes to create technologies and products for a wide variety of challenges. Under evaluation this morning are these four equities: Ocular Therapeutix Inc. (NASDAQ: OCUL), Onconova Therapeutics Inc. (NASDAQ: ONTX), OPKO Health Inc. (NASDAQ: OPK), and Otonomy Inc. (NASDAQ: OTIC). All you have to do is sign up today for this free limited time offer by clicking the link below.
On Monday, shares in Bedford, Massachusetts headquartered Ocular Therapeutix Inc. recorded a trading volume of 158,186 shares. The stock ended at $6.39, declining 1.39% from the last trading session. The Company’s shares have gained 14.11% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 8.67% and 9.89%, respectively. Furthermore, shares of Ocular Therapeutix, which focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology, have a Relative Strength Index (RSI) of 52.97. Get the full research report on OCUL for free by clicking below at:
Newtown, Pennsylvania headquartered Onconova Therapeutics Inc.’s stock finished yesterday’s session 0.65% lower at $0.78 with a total trading volume of 71,763 shares. The stock is trading below their 50-day moving average by 23.47%. Shares of the Company, which focuses on discovering and developing small molecule drug candidates to treat cancer, have an RSI of 35.25.
On March 26th, 2018, Onconova Therapeutics announced that it presented promising, new clinical safety data from the expansion phase of a Phase-2 clinical trial at the Bone Marrow Failure Disease Scientific Symposium. In the new study, in 37 patients studied with oral rigosertib (total dose of 1120 mg/day 3 out of 4 weeks) and azacitidine employing prophylactic risk-mitigating strategies to minimize hematuria, a significantly lower incidence of grade 1 & 2 hematuria (11%) and no grade 3 or 4 hematuria have been seen to date. The free technical report on ONTX can be accessed at:
At the close of trading on Monday, shares in Miami, Florida headquartered OPKO Health Inc. climbed 1.00%, ending the day at $3.02. The stock recorded a trading volume of 2.75 million shares. The Company’s shares are trading 13.94% below their 50-day moving average. Moreover, shares of OPKO Health, which engages in the diagnostics and pharmaceuticals business in the US, Ireland, Chile, Spain, Israel, Mexico, and internationally, have an RSI of 38.86.
On March 23rd, 2018, OPKO Health has enrolled the first patient in a Phase-2b dose escalation trial of OPK88003, a once-weekly oxyntomodulin therapy containing dual agonist activity towards GLP-1 and Glucagon receptors, to treat type-2 diabetes and obesity. Based on preclinical and Phase-2 data, the use of once-weekly dual agonists, such as OPK88003, could more effectively improve glucose control, increase weight loss, and improve the lipid profile in type-2 diabetics compared to the current GLP—1 therapies on the market. Sign up for free on Wall St. Equities and claim the latest report on OPK at:
San Diego, California headquartered Otonomy Inc.’s shares ended the day 4.71% lower at $4.05 with a total trading volume of 383,589 shares. The stock is trading 19.31% below its 50-day moving average. Shares of the Company, which engages in the development and commercialization of therapeutics for otology in the US, have an RSI of 38.29.
On March 19th, 2018, research firm JP Morgan downgraded the Company’s stock rating from ‘Neutral’ to ‘Underweight’. See the free research coverage on OTIC at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-biotech-stocks—-ocular-therapeutix-onconova-therapeutics-opko-health-and-otonomy-300631111.html
SOURCE Wall St. Equities
To post and circulate your own press release on FIR and the eTN Network please click here